A Phase 3 interventional study of Upadacitinib and Placebo in Rheumatoid Arthritis (RA), sponsored by AbbVie. Completed at 43 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-27.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 10th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18–65
AbbVie
Ages 18+
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2012; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 338 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 300 across the 19 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 12th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2018, is one of 11 in phase 3, and was the 59th registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, from their registry updates:
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The study objectives of Period 1 of this study were to compare the efficacy, safety, and tolerability of upadacitinib versus placebo for the treatment of signs and symptoms of subjects from China and selected countries including Brazil and South Korea with moderately to severely active rheumatoid arthritis (RA) who are on a stable dose of csDMARDs and have an inadequate response to csDMARDs.
The study objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib in subjects with RA who have completed Period 1.
This is a Phase 3 multicenter study that includes two periods. Period 1 is a 12-week, randomized, double-blind, parallel-group, placebo-controlled period designed to compare the safety and efficacy of upadacitinib versus placebo for the treatment of signs and symptoms of participants with moderately to severely active RA who are on a stable dose of csDMARDs and have an inadequate response to csDMARDs. Period 2 is an open label 52 week extension period to evaluate the long-term safety, tolerability, and efficacy of upadacitinib in participants with RA who have completed Period 1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug.
Participant meets both of the following disease activity criteria:
Participants with prior exposure to at most one biological disease-modifying anti-rheumatic drugs (bDMARD) may be enrolled (up to 20% of total number of subjects). Specifically, prior to enrollment:
Exclusion Criteria:
Participants randomized to receive placebo once daily for 12 weeks in Period 1 followed by upadacitinib 15 mg once daily for up to 52 weeks in Period 2.
Drug: Upadacitinib · Drug: Placebo
Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1 and up to an additional 52 weeks in Period 2.
Drug: Upadacitinib
Tablets for oral administration
Also known as: ABT-494, RINVOQ™
Tablets for oral administration
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Change From Baseline in Disease Activity Score Based on CRP (DAS28 [CRP]) at Week 12
The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.
Time frame: Baseline and Week 12
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12
Low disease activity based on DAS28 (CRP) is defined a DAS28 (CRP) score of ≤ 3.2. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.
Time frame: Week 12
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12
Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) score of less than 2.6. DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity.
Time frame: Week 12
Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) at Week 12
Low disease activity based on CDAI is defined as a CDAI score ≤ 10. CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity.
Time frame: Week 12
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 1
Participants were enrolled at 37 sites in Brazil, China, and South Korea. The study consisted of a 12-week placebo-controlled, double-blind period (Period 1), and an open-label 52-week extension period (Period 2).
| Milestone | Placebo / Upadacitinib 15 mg | Upadacitinib 15 mg / Upadacitinib 15 mg |
|---|---|---|
| Started | 169 | 169 |
| Completed | 153 | 157 |
| Not completed | 16 | 12 |
| Withdrew: Adverse event | 4 | 7 |
| Withdrew: Withdrawal by subject | 8 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Other | 3 | 2 |
| Milestone | Placebo / Upadacitinib 15 mg | Upadacitinib 15 mg / Upadacitinib 15 mg |
|---|---|---|
| Started | 153 | 157 |
| Completed | 136 | 139 |
| Not completed | 17 | 18 |
| Withdrew: Adverse event | 11 | 7 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Lack of efficacy | 3 | 2 |
| Withdrew: Covid-19 logistical restrictions | 0 | 1 |
| Withdrew: Other | 2 | 4 |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg |
|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 31.4 (24.4 to 38.4) | 71.6 (64.8 to 78.4) |
The DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.
| units on a scale | Placebo | Upadacitinib 15 mg |
|---|---|---|
| Change From Baseline in Disease Activity Score Based on CRP (DAS28 [CRP]) at Week 12 | -0.95 (-1.16 to -0.74) | -2.56 (-2.76 to -2.36) |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
| units on a scale | Placebo | Upadacitinib 15 mg |
|---|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | -0.18 (-0.28 to -0.09) | -0.62 (-0.71 to -0.54) |
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from baseline score indicates an improvement.
| units on a scale | Placebo | Upadacitinib 15 mg |
|---|---|---|
| Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 | 3.36 (2.25 to 4.48) | 8.93 (7.80 to 10.07) |
Low disease activity based on DAS28 (CRP) is defined a DAS28 (CRP) score of ≤ 3.2. The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity. A DAS28 score less than or equal to 3.2 indicates low disease activity.
| percentage of participants | Placebo | Upadacitinib 15 mg |
|---|---|---|
| Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28 (CRP) at Week 12 | 13.6 (8.4 to 18.8) | 46.2 (38.6 to 53.7) |
Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) score of less than 2.6. DAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to 10, where higher scores indicate more disease activity.
| percentage of participants | Placebo | Upadacitinib 15 mg |
|---|---|---|
| Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12 | 5.3 (1.9 to 8.7) | 29.6 (22.7 to 36.5) |
Low disease activity based on CDAI is defined as a CDAI score ≤ 10. CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 76 with higher scores indicating higher disease activity.
| percentage of participants | Placebo | Upadacitinib 15 mg |
|---|---|---|
| Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) at Week 12 | 11.2 (6.5 to 16.0) | 35.5 (28.3 to 42.7) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg |
|---|---|---|
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 8.3 (4.1 to 12.4) | 40.8 (33.4 to 48.2) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg |
|---|---|---|
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 3.6 (0.8 to 6.3) | 21.3 (15.1 to 27.5) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg |
|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1 | 5.9 (2.4 to 9.5) | 25.4 (18.9 to 32.0) |
Collected over Period 1: From the first dose of study drug up to Week 12 or up to 30 days after last dose for participants who discontinued study drug prior to Week 12. Period 2: From Week 12 to 30 days after last dose; up to 56 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Placebo | 0/169 (0%) | 5/169 (3%) | 13/169 (7.7%) |
| Period 1: Upadacitinib 15 mg | 0/169 (0%) | 12/169 (7.1%) | 25/169 (14.8%) |
| Period 1+2: Upadacitinib 15 mg | 0/322 (0%) | 55/322 (17.1%) | 198/322 (61.5%) |
| Event | Period 1: Placebo | Period 1: Upadacitinib 15 mg | Period 1+2: Upadacitinib 15 mg |
|---|---|---|---|
| PNEUMONIAInfections and infestations | 1/169 | 3/169 | 8/322 |
| HERPES ZOSTERInfections and infestations | 0/169 | 1/169 | 4/322 |
| TENDON RUPTUREInjury, poisoning and procedural complications | 0/169 | 2/169 | 2/322 |
| CHOLELITHIASISHepatobiliary disorders | 0/169 | 0/169 | 3/322 |
| APPENDICITISInfections and infestations | 0/169 | 0/169 | 2/322 |
| POSTOPERATIVE WOUND INFECTIONInfections and infestations | 0/169 | 0/169 | 2/322 |
| ANKLE FRACTUREInjury, poisoning and procedural complications | 0/169 | 0/169 | 2/322 |
| DRUG-INDUCED LIVER INJURYHepatobiliary disorders | 1/169 | 0/169 | 0/322 |
| ANAPHYLACTIC REACTIONImmune system disorders | 0/169 | 1/169 | 0/322 |
| MENISCUS INJURYInjury, poisoning and procedural complications | 0/169 | 1/169 | 1/322 |
| Event | Period 1: Placebo | Period 1: Upadacitinib 15 mg | Period 1+2: Upadacitinib 15 mg |
|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 11/169 | 16/169 | 65/322 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 2/169 | 9/169 | 30/322 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 0/169 | 0/169 | 29/322 |
| HEPATIC FUNCTION ABNORMALHepatobiliary disorders | 0/169 | 0/169 | 27/322 |
| ANAEMIABlood and lymphatic system disorders | 0/169 | 0/169 | 26/322 |
| LEUKOPENIABlood and lymphatic system disorders | 0/169 | 0/169 | 26/322 |
| NASOPHARYNGITISInfections and infestations | 0/169 | 0/169 | 24/322 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 0/169 | 0/169 | 24/322 |
| HERPES ZOSTERInfections and infestations | 0/169 | 0/169 | 23/322 |
| WEIGHT INCREASEDInvestigations | 0/169 | 0/169 | 23/322 |
The Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | Upadacitinib 15 mg | Total |
|---|---|---|---|
| Mean | 51.7 ± 11.39 | 51.7 ± 10.63 | 51.7 ± 11.00 |
| Sex: Female, Male(Participants) | Placebo | Upadacitinib 15 mg | Total |
|---|---|---|---|
| Female | 139 | 135 | 274 |
| Male | 30 | 34 | 64 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Upadacitinib 15 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 21 | 24 | 45 |
| Not Hispanic or Latino | 148 | 145 | 293 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Upadacitinib 15 mg | Total |
|---|---|---|---|
| White | 19 | 19 | 38 |
| Black or African American | 3 | 3 | 6 |
| American Indian/Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| Asian | 142 | 141 | 283 |
| Multiple | 5 | 6 | 11 |
| Enrollment by Country(Participants) | Placebo | Upadacitinib 15 mg | Total |
|---|---|---|---|
| China | 114 | 114 | 228 |
| South Korea | 29 | 29 | 58 |
| Brazil | 26 | 26 | 52 |
| Duration Since Rheumatoid Arthritis (RA) Diagnosis(years) | Placebo | Upadacitinib 15 mg | Total |
|---|---|---|---|
| Mean | 7.5 ± 7.55 | 7.2 ± 7.16 | 7.3 ± 7.35 |
| Tender Joint Count(joints) | Placebo | Upadacitinib 15 mg | Total |
|---|---|---|---|
| Mean | 23.0 ± 14.45 | 21.5 ± 14.84 | 22.3 ± 14.64 |
| Swollen Joint Count(joints) | Placebo | Upadacitinib 15 mg | Total |
|---|---|---|---|
| Mean | 11.9 ± 6.00 | 11.9 ± 6.89 | 11.9 ± 6.45 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Jan 2018 to primary completion in Aug 2019, 19 months.
Results were first posted in Aug 2020, 11 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 19 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib